Printer Friendly

CENTOCOR EXERCISES CPII PURCHASE OPTION

 CENTOCOR EXERCISES CPII PURCHASE OPTION
 MALVERN, Pa., Feb. 21 /PRNewswire/ -- Centocor, Inc. (NASDAQ: CNTO)


said today that it is exercising its option to purchase the limited partnership interests in Centocor Partners II, L.P. (CPII).
 By exercising the option, Centocor retains rights to the products developed on behalf of CPII, which are HA-1A, a human monoclonal antibody directed against the endotoxin of gram negative bacteria, and also certain cancer imaging agents.
 Centocor expects shortly to complete the distribution of an aggregate $12.4 million to the limited partners of CPII, representing the advance payment owed pursuant to the exercise of the purchase option. Centocor will also make future payments based upon sales of the products developed by CPII, which raised $55 million in 1986 to fund the development of those products.
 In December 1990, Centocor announced that it intended to exercise its options to purchase the limited partnership interests of CPII and of another research-and-development partnership, called Centocor Cardiovascular Imaging Partners, L.P. Accordingly, Centocor in the fourth quarter of 1990 recorded a related charge to earnings of $115.5 million for acquired research and development.
 Centocor, based in Malvern, develops, manufactures, and markets diagnostic and pharmaceutical products for human health care. The company's products are based on monoclonal antibody technology and are primarily intended for use in the management of patients with infectious, cardiovascular and autoimmune disease, and cancer.
 /delval/
 -0- 2/21/92
 /CONTACT: Richard M. Koenig of Centocor, 215-651-6122/
 (CNTO) CO: Centocor, Inc.; Centocor Partners II, L.P. ST: Pennsylvania IN: MTC SU:


LJ -- PH003 -- 1256 02/21/92 08:58 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 21, 1992
Words:265
Previous Article:GERBER SCIENTIFIC REPORTS RESULTS
Next Article:DU PONT TO HOLD FIRST SAE NEWS CONFERENCE MONDAY, FEB. 24
Topics:


Related Articles
CENTOCOR COMMENCES OFFER TO EXCHANGE STOCK FOR TOCOR II UNITS
CENTOCOR TO EXTEND TOCOR II OFFER
Centocor Exercises Option for Four Exclusive Commercial Licenses to Medarex's HuMAb-Mouse Technology.
Centocor Expands Clinical Development Program.
Centocor Reaches Agreement to Sell Oncology Diagnostics Business.
Johnson & Johnson Announces Redemption of Centocor 4.75% Convertible Debentures Due February 2005.
MorphoSys Announces Expanded Agreement with Centocor.
Centocor Extends License to MorphoSys Therapeutic Antibody.
Centocor, Schering-Plough revise agreement covering REMICADE, Golimumab.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters